Kedrion S.p.A.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$1.6M
Doctors Paid
2
Transactions
151
2024 Total
$7,659
Payment Breakdown by Category
Research$1.6M (96.2%)
Consulting$50,085 (3.1%)
Travel$9,923 (0.6%)
Food & Beverage$126.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 130 | 96.2% |
| Consulting Fee | $50,085 | 4 | 3.1% |
| Travel and Lodging | $9,923 | 7 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,050 | 1 | 0.1% |
| Education | $915.12 | 8 | 0.1% |
| Food and Beverage | $126.00 | 1 | 0.0% |
Payments by Type
Research
$1.6M
130 transactions
General
$62,099
21 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients | $1.4M | 0 | 122 |
| A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis | $58,439 | 0 | 1 |
| INDIVIDUAL PATIENT IND FOR TREATMENT USE | $47,623 | 0 | 1 |
| COMPASSIONATE USE OF KEDRION HUMAN PLASMINOGEN OPHTHALMOLOGIC DROP PREPARATION IN PATIENTS DIAGNOSED WITH LIGNEOUS CONJUNCTIVITIS: INTERMEDIATE SIZE PATIENT POPULATION EXPANDED ACCESS PROTOCOL | $47,623 | 0 | 1 |
| Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population | $21,178 | 0 | 3 |
| A Historically-Controlled Phase II/III study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed with Ligneous Conjunctivitis | $16,984 | 0 | 1 |
| Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients | $6,075 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatric Hematology-Oncology | $50,085 | 1 | $50,085 |
| Specialist | $12,014 | 1 | $12,014 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Amy Shapiro, Md, MD | Pediatric Hematology-Oncology | Indianapolis, IN | $50,085 | $0 |
| Dr. William Lumry, M.d, M.D | Specialist | Dallas, TX | $12,014 | $0 |
Ad
Top Products
- IVIG 10% $1.4M
- Human Plasminogen $125,750
Associated Products (2)
- IVIG 10% $1.4M
- Human Plasminogen $125,750
Payment Categories
- Food & Beverage $126.00
- Consulting $50,085
- Travel & Lodging $9,923
- Research $1.6M
About Kedrion S.p.A.
Kedrion S.p.A. has made $1.6M in payments to 2 healthcare providers, recorded across 151 transactions in the CMS Open Payments database. In 2024, the company paid $7,659. The top product by payment volume is IVIG 10% ($1.4M).
Payments were distributed across 2 medical specialties. The top specialty by payment amount is Pediatric Hematology-Oncology ($50,085 to 1 doctors).
Payment categories include: Food & Beverage ($126.00), Consulting ($50,085), Research ($1.6M), Travel & Lodging ($9,923).
Kedrion S.p.A. is associated with 2 products in the CMS Open Payments database.